Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

NCT03002077 is registered in ClinicalTrials.gov with Naurex, Inc, an affiliate of Allergan plc as lead sponsor.

NCT NCT03002077
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03002077 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder
Lead sponsor
Naurex, Inc, an affiliate of Allergan plc
Phase
Phase 3
Overall status
Completed
Start date
February 3, 2017
Completion date
December 6, 2018
Enrollment
617 (actual)
Sites
128

Conditions

As the registry lists them; a condition with its own page is linked.

depressive disorder, major